Sonnet biotherapeutics expands clinical evaluation of son-1010 dose escalation with atezolizumab in ovarian cancer

Sonnet's lead product, son-1010 (il12-f h ab), is being evaluated in combination with atezolizumab (tecentriq ® ) in patients with advanced platinum-resistant ovarian cancer (proc) (sb221)
SONN Ratings Summary
SONN Quant Ranking